BCNI Clinical Trials

See our short film which gives one Irish patient's experience on a clinical trial and gives an overview of clinical trials by Prof Michael O'Dwyer, Director of Blood Cancer Newtork Ireland

BCNI will carry out early phase (Phase I) clinical trials in cancer care centres in Galway, Cork and Dublin. Clinical trials are designed to develop and test new and improved ways to treat cancer in people; help prevent a return of cancer; and improve comfort and quality of life for people with cancer. Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies. BCNI trials will focus on novel targeted approaches, including immunotherapy.

Please see here for  Patient information leaflet -Clinical trials

Clinical trials are designed to develop and test new and improved therapies

New therapies are usually developed and tested in a laboratory. Then they are thoroughly tested in animals. If the early research (the preclinical trials) shows the therapy is safe and effective, a carefully planned and monitored clinical trial of the drug or treatment will then be conducted in people. 

 

‌ 

Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies.

  • The BCNI will carry out early phase (phase I) clinical trials in cancer care centres in strategic geographical locations (Galway, Cork & Dublin) under a single unified structure.  

  • This will be led by University Hospital Galway, which has well established phase I trial expertise for blood cancers and phase I capability will be rapidly extended to the other centres (St James’s Hospital, Mercy University Hospital, Cork University Hospital, Beaumont hospital and the Mater hospital).

  • The cohesive and national structure of the BCNI will make Ireland an attractive place for industry and clinical researchers to carry out their clinical trials. The main advantage of this is that it will provide Irish patients with easier access to novel experimental drugs and provide them with a very high level of care and attention.

 

ACTIVE CLINICAL TRIALS

Please see below for our clinical trials that are currently active and enrolling participants

Multiple Myeloma
Study Title
Patient Population
BCNI Sites Open for Enrollment
ClinicalTrials.gov link for further study info
Study Contacts
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma Relapsed/Refractory Multiple Myeloma

Galway University Hospital

Beaumont Hospital

Cork University Hospital

GMI1271-230

GUH: Jessica Walsh +353 (0)91 893314

Beaumont Hospital: Tara Kenny +353 (0)18 09 2080

Cork University Hospital: Contact:Debra O’Hare+353 (0)21 49 20051 

Multiple Myeloma 
Study Title
Patient Population
BCNI Sites Planned for involvement
ClinicalTrials.gov link for further study info
Study Contacts
Phase Ib study of weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) withDaratumumab (DARA) in transplant eligible patientswith newly diagnosed Multiple Myeloma (MM). “TheCyBorD-DARA study” Newly Diagnosed Multiple Myeloma

Currently open and recruiting in Galway University Hospital and Cork University Hospital.

Beaumont and the Mater will open in 2017

CyBorD-Dara

GUH:PI: Professor Michael O’DwyerContact:Jessica Walsh +353 (0)91 893314 

The Mater:PI: Professor Peter O’GormanContact: Martina Smith+353 (0)18 03 4838  

Cork University Hospital:PI: Professor Mary CahillContact:Debra O’Hare+353 (0)21 49 20051 

Beaumont:PI: Dr. John QuinnContact:Tara Kenny +353 (0)18 09 2080 

St James:PI: Dr. Patrick Hayden+353 (0)14 16 2212

 
Acute Myeloid Leukemia
Study Title
Patient Population
BCNI Sites Open for Enrollment
ClinicalTrials.gov link for further study info
Study Contacts
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
  1. Age >18y/o Relapsed/Refractory AML
2. Age >60y/o newly diagnosed AML
Galway University Hospital GMI1271-201 GUH: Jessica Walsh  +353 (0)91 893314

UPCOMING CLINICAL TRIALS

3 studies curently open and recruiting

No new trails planned for the moment